- Home
- CERO vs STRR Comparison
CERO vs STRR Comparison
Compare CERO & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- STRR
- Stock Information
- Founded
- CERO 2017
- STRR 1985
- Country
- CERO United States
- STRR United States
- Employees
- CERO N/A
- STRR N/A
- Industry
- CERO
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CERO
- STRR Health Care
- Exchange
- CERO Nasdaq
- STRR Nasdaq
- Market Cap
- CERO 3.5M
- STRR 6.3M
- IPO Year
- CERO N/A
- STRR N/A
- Fundamental
- Price
- CERO $9.40
- STRR N/A
- Analyst Decision
- CERO Strong Buy
- STRR Strong Buy
- Analyst Count
- CERO 2
- STRR 1
- Target Price
- CERO $45.00
- STRR $5.00
- AVG Volume (30 Days)
- CERO 3.3M
- STRR 14.1K
- Earning Date
- CERO 08-13-2025
- STRR 08-12-2025
- Dividend Yield
- CERO N/A
- STRR N/A
- EPS Growth
- CERO N/A
- STRR N/A
- EPS
- CERO N/A
- STRR N/A
- Revenue
- CERO N/A
- STRR $57,165,000.00
- Revenue This Year
- CERO N/A
- STRR $33.64
- Revenue Next Year
- CERO N/A
- STRR $22.87
- P/E Ratio
- CERO N/A
- STRR N/A
- Revenue Growth
- CERO N/A
- STRR 34.33
- 52 Week Low
- CERO $6.71
- STRR $1.72
- 52 Week High
- CERO $895.40
- STRR $5.35
- Technical
- Relative Strength Index (RSI)
- CERO 47.17
- STRR 42.11
- Support Level
- CERO $9.10
- STRR $1.95
- Resistance Level
- CERO $9.73
- STRR $2.04
- Average True Range (ATR)
- CERO 2.73
- STRR 0.06
- MACD
- CERO 0.08
- STRR -0.00
- Stochastic Oscillator
- CERO 12.57
- STRR 0.00
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.